Cargando…
Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics
BACKGROUND: Some hemodialysis patients require large doses of erythropoiesis-stimulating agents (ESAs) to manage anemia. These patients, termed “ESA hyporesponsive,” have been characterized using various definitions. We applied three definitions of hyporesponsiveness to a large, national cohort of h...
Autores principales: | Gilbertson, David T, Peng, Yi, Arneson, Thomas J, Dunning, Stephan, Collins, Allan J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586346/ https://www.ncbi.nlm.nih.gov/pubmed/23425362 http://dx.doi.org/10.1186/1471-2369-14-44 |
Ejemplares similares
-
Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023) -
Epoetin alfa resistance in hemodialysis patients with chronic kidney
disease: a longitudinal study
por: Santos, E.J.F., et al.
Publicado: (2018) -
Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
por: Arrieta, Javier, et al.
Publicado: (2014) -
Evaluation of a biosimilar recombinant alpha epoetin in the management of anemia in hemodialysis patients
por: Beiraghdar, Fatemeh, et al.
Publicado: (2015) -
Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients
por: Sibbel, Scott P., et al.
Publicado: (2015)